According to one study, based on modeled concentrations, pre-Anthropocene tissue-bound levels in fish may not have differed markedly from current levels. However, based on a comprehensive set of global measurements, the ocean contains about 60,000 to 80,000 tons of mercury from pollution, and mercury levels in the upper ocean have tripled since the beginning of the industrial revolution. Higher mercury levels in shallower ocean waters could increase the amount of the toxicant accumulating in food fish, exposing people to a greater risk of mercury poisoning. See also
Canadian Reference Materials include some with methylmercury, e.g. DORM
Dimethylmercury, mercury with a second methyl group
Ethylmercury, a related cation
Mercury poisoning
Mercury regulation in the United States

References
External links
ATSDR - ToxFAQs: Mercury
ATSDR - Public Health Statement: Mercury
ATSDR - ALERT! Patterns of Metallic Mercury Exposure, 6/26/97
ATSDR - MMG: Mercury
ATSDR - Toxicological Profile: Mercury
National Pollutant Inventory - Mercury and compounds Fact Sheet
Methylmercury-in-fish exposure calculator provided by GotMercury.Org, which uses FDA mercury data with the EPAs calculated safe exposure levels. Methylmercury Contamination in Fish and Shellfish Archived 2013-11-02 at the Wayback Machine
nytimes.com, Tuna Fish Stories: The Candidates Spin the Sushi
U.S. Environmental Protection Agencys mercury site
U.S. Geological Surveys mercury site Archived 2013-11-02 at the Wayback Machine
Environment Canadas mercury site
Health Canadas mercury site
International Conference on Mercury as a Global Pollutant 2006-Madison, WI USA  2009-Guizhou, China  2011-Halifax, NS Canada
Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1).The most common side effects include injection site reactions and abdominal pain.Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) that reduces levels of glycolate oxidase (GO) enzyme by targeting the HAO1 messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. Decreased GO enzyme levels reduce the amount of available glyoxylate, a substrate for oxalate production. This results in reduction of urinary and plasma oxalate levels, the underlying cause of disease manifestations in people with PH1. As the GO enzyme is upstream of the deficient alanine:glyoxylate aminotransferase (AGT) enzyme that causes PH1, the mechanism of action of lumasiran is independent of the underlying AGXT gene mutation.Lumasiran was approved for medical use in the European Union and in the United States in November 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses
Lumasiran is indicated for the treatment of primary hyperoxaluria type 1 (PH1) in adults and children of all ages.PH1 is a rare illness that causes the liver to produce an excessive amount of oxalate. Oxalate is removed by the kidneys and through the urine. In people with PH1, the extra oxalate can cause kidney stones and kidney failure. The extra oxalate can also build up, and damage other parts of the body, including eyes, heart, skin, and bone. This is called oxalosis.